Dr Reddy's Labs launches Desmopressin Acetate Injection in US

Hyderabad and Princeton: Dr Reddy's Laboratories Ltd. today announced the launch of Desmopressin Acetate Injection USP, 4 mcg/mL Single-dose Ampules, a therapeutic equivalent generic version of DDAVP (desmopressin acetate) Injection, 4 mcg/mL, approved by the U.S. Food and Drug Administration (USFDA).

The DDAVP (desmopressin acetate) Injection USP brand and the generic market had U.S. sales of approximately $20.9 million MAT for the most recent twelve months ending in March 2020 according to IQVIA Health*.

Marc Kikuchi, CEO, North America Generics, Dr Reddy's Laboratories, commented, "The launch of Desmopressin Injection demonstrates a strong, growing collaboration with SunGen Pharma. We look forward to future opportunities with this company."

Isaac Liu, Ph.D., Co-CEO of SunGen, stated, "We are pleased to be working with Dr Reddy's for this launch. The launch of Desmopressin demonstrates our strong development capabilities. We look forward to collaborating further to bring speciality pharmaceutical drugs to the markets around the world."

Dr Reddy's Desmopressin Acetate Injection USP, 4 mcg/mL is available in a carton of ten 1 mL single-dose ampules. 

Read also: India Ratings and Research assigns A1-plus rating to Dr Reddy's commercial papers